PMID- 36861520
OWN - NLM
STAT- MEDLINE
DCOM- 20230303
LR  - 20230303
IS  - 1998-4774 (Electronic)
IS  - 0019-509X (Linking)
VI  - 59
IP  - 4
DP  - 2022 Oct-Dec
TI  - Atypical MYC rearrangement pattern of 3' deletion and 5' amplification along with 
      independent IGH rearrangement: A case study.
PG  - 548-551
LID - 10.4103/ijc.IJC_1292_20 [doi]
AB  - A spectrum of Cellular homolog of the v-myc oncogene (cMYC) alterations such as 
      translocation, overexpression, mutation, and amplification plays an important 
      role in lymphomagenesis, particularly in high-grade lymphomas, and are associated 
      with prognostic significance. Accurate identification of cMYC gene alteration is 
      important for diagnostic, prognostic, and therapeutic implications. With the 
      application of different FISH (fluorescence in situ hybridization) probes that 
      helped overcome the analytical diagnostic challenges as a result of variant 
      patterns, we report rare, concomitant, and independent gene alterations in cMYC 
      and Immunoglobulin heavy-chain gene (IGH) with detailed characterization of its 
      variant rearrangement. Short-term follow-up post R-CHOP (rituximab plus 
      cyclophosphamide, doxorubicin, vincristine, and prednisone) therapy seemed to be 
      favorable. Accumulation of many more literature studies on such cases with their 
      therapeutic implications would lead to the categorization of these cases as a 
      separate subclass in large B-cell lymphomas followed by molecular targeted 
      therapy.
FAU - Kandoor, Sandhya
AU  - Kandoor S
AD  - Department of Cytogenetics, SRL Diagnostics Ltd, Mumbai, Maharashtra, India.
FAU - Kate, Ushang
AU  - Kate U
AD  - Department of Cytogenetics, SRL Diagnostics Ltd, Mumbai, Maharashtra, India.
FAU - Deb, Prabal
AU  - Deb P
AD  - Department of Cytogenetics, SRL Diagnostics Ltd, Mumbai, Maharashtra, India.
FAU - Mehta, Sangita S
AU  - Mehta SS
AD  - Department of Medical Oncology, Kovai Medical Center and Hospital Institute of 
      Health Sciences and Research, Coimbatore, India.
FAU - Kanda Kumar, B Vignesh
AU  - Kanda Kumar BV
AD  - Department of Medical Oncology, Kovai Medical Center and Hospital Institute of 
      Health Sciences and Research, Coimbatore, India.
FAU - Pais, Anurita P
AU  - Pais AP
AD  - Department of Cytogenetics, SRL Diagnostics Ltd, Mumbai, Maharashtra, India.
LA  - eng
PT  - Case Reports
PL  - India
TA  - Indian J Cancer
JT  - Indian journal of cancer
JID - 0112040
RN  - 8N3DW7272P (Cyclophosphamide)
RN  - 80168379AG (Doxorubicin)
SB  - IM
MH  - Humans
MH  - In Situ Hybridization, Fluorescence
MH  - Cyclophosphamide
MH  - Doxorubicin
MH  - *Lymphoma, Large B-Cell, Diffuse
MH  - *Lymphoma, Non-Hodgkin
OTO - NOTNLM
OT  - FISH
OT  - IGH
OT  - Lymphoma
OT  - cMYC
EDAT- 2023/03/03 06:00
MHDA- 2023/03/04 06:00
CRDT- 2023/03/02 05:25
PHST- 2023/03/02 05:25 [entrez]
PHST- 2023/03/03 06:00 [pubmed]
PHST- 2023/03/04 06:00 [medline]
AID - IndianJournalofCancer_2022_59_4_548_370638 [pii]
AID - 10.4103/ijc.IJC_1292_20 [doi]
PST - ppublish
SO  - Indian J Cancer. 2022 Oct-Dec;59(4):548-551. doi: 10.4103/ijc.IJC_1292_20.